Regeneron Pharmaceuticals Inc (REGN)
Total asset turnover
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 13,044,200 | 12,113,500 | 16,014,400 | 8,440,200 | 7,833,200 |
| Total assets | US$ in thousands | 33,080,200 | 29,214,500 | 25,434,800 | 17,163,300 | 14,805,200 |
| Total asset turnover | 0.39 | 0.41 | 0.63 | 0.49 | 0.53 |
December 31, 2023 calculation
Total asset turnover = Revenue ÷ Total assets
= $13,044,200K ÷ $33,080,200K
= 0.39
Regeneron Pharmaceuticals, Inc.'s total asset turnover has shown fluctuating trends over the past five years. In 2023, the total asset turnover ratio decreased to 0.40 from 0.42 in 2022, indicating that the company generated $0.40 in revenue for every dollar of assets during the period. This decline may suggest lower efficiency in utilizing its assets to generate sales.
Comparing to 2021 when the total asset turnover was at 0.63, the ratio has decreased significantly, implying a potential decrease in asset efficiency. However, it is worth noting that the total asset turnover in 2023 was still higher than that of 2020 and 2019, which were 0.50 and 0.53, respectively.
Overall, the decreasing trend in total asset turnover over the past two years raises questions about Regeneron Pharmaceuticals, Inc.'s ability to effectively utilize its assets to generate revenue. Further investigation into the company's asset management and operational efficiency may be warranted to address the declining trend in total asset turnover.
Peer comparison
Dec 31, 2023